Carteolol long-acting ophthalmic solution — Competitive Intelligence Brief

Carteolol long-acting ophthalmic solution (Carteolol long-acting ophthalmic solution) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-adrenergic receptor antagonist (non-selective beta-blocker). Area: Ophthalmology.

phase 3 Beta-adrenergic receptor antagonist (non-selective beta-blocker) Beta-1 and beta-2 adrenergic receptors Ophthalmology Small molecule

Target snapshot

Carteolol long-acting ophthalmic solution (Carteolol long-acting ophthalmic solution) — Otsuka Pharmaceutical Co., Ltd.. Carteolol is a non-selective beta-adrenergic receptor antagonist that reduces intraocular pressure by decreasing aqueous humor production in the eye.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Carteolol long-acting ophthalmic solution TARGET	Carteolol long-acting ophthalmic solution	Otsuka Pharmaceutical Co., Ltd.	phase 3	Beta-adrenergic receptor antagonist (non-selective beta-blocker)	Beta-1 and beta-2 adrenergic receptors
Timolol 0.5% Ophthalmic Solution	Timolol 0.5% Ophthalmic Solution	University of California, Davis	marketed	Beta-adrenergic antagonist	Beta-1 and beta-2 adrenergic receptors
treatment with brimonidine/timolol	treatment with brimonidine/timolol	Aristotle University Of Thessaloniki	marketed	Alpha-2 adrenergic agonist / Beta-blocker combination	Alpha-2 adrenergic receptor; Beta-1 and Beta-2 adrenergic receptors
Hydrocortisone/ Placebo and Propranolol	Hydrocortisone/ Placebo and Propranolol	University of Dundee	marketed	Glucocorticoid + Beta-blocker combination	Glucocorticoid receptor; Beta-1 and Beta-2 adrenergic receptors
tafluprost and dorzolamide/timolol	tafluprost and dorzolamide/timolol	Aristotle University Of Thessaloniki	marketed	Prostaglandin analogue / carbonic anhydrase inhibitor / beta-blocker combination	Prostaglandin F receptor (FP receptor), carbonic anhydrase II, beta-1 and beta-2 adrenergic receptors
RASi plus carvedilol	RASi plus carvedilol	Federal University of Minas Gerais	marketed	ACE inhibitor or ARB combined with non-selective beta-blocker	Angiotensin II receptor / ACE enzyme; beta-1 and beta-2 adrenergic receptors; alpha-1 adrenergic receptor
Brimonidine/Timolol mixed combination	Brimonidine/Timolol mixed combination	Seoul National University Hospital	marketed	Alpha-2 adrenergic agonist / Beta-blocker combination	Alpha-2 adrenergic receptor; Beta-1 and Beta-2 adrenergic receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-adrenergic receptor antagonist (non-selective beta-blocker) class)

1. Otsuka Pharmaceutical Co., Ltd. · 1 drug in this class